Roche and Genentech told Huntington's disease patient organisations on 9 July 2026 that they had discontinued clinical development of two antisense drugs, tominersen and RG6496. In a letter signed by Mai-Lise Nguyen, the company said the phase 2 GENERATION HD2 study (NCT05686551) met its safety and biomarker objectives but did not meet its efficacy objective. The study randomised 301 participants aged 25 to 50 with prodromal or early manifest disease to intrathecal tominersen or placebo, given every four months for a minimum of about 16 months, with the 100 mg dose carried forward after an interim review in April 2025. Roche reported that tominersen was well tolerated with no new safety signals, that it significantly lowered mutant huntingtin protein and neurofilament light chain (NfL, a marker of nerve cell damage) in cerebrospinal fluid compared with placebo, and that there was no meaningful effect on clinical measures, assessed with the composite Unified Huntington's Disease Rating Scale (cUHDRS) and Total Functional Capacity (TFC). These are top-line results from a primary analysis; the full dataset has not been peer reviewed or published, and Roche said it intends to share the data with the research community.
The result is a direct test of a premise that has shaped much of the Huntington's field: that lowering the mutant protein, and moving a fluid marker of neuronal injury, should translate into slower decline. Tominersen, licensed by Roche from Ionis in 2017, had already failed once. Dosing in the phase 3 GENERATION HD1 trial was halted in March 2021, and an ad hoc analysis at week 69, published as a letter in the New England Journal of Medicine in December 2023, reported worse outcomes at the higher exposure alongside post hoc signals that younger participants with less disease burden might fare better. GENERATION HD2 was built to test that hypothesis prospectively. It did not confirm it.
The second decision was unrelated to that dataset. POINT-HD (NCT07246941), a phase 1 first-in-human study of RG6496, an antisense drug designed to lower only the expanded copy of huntingtin by targeting a single nucleotide difference on the mutant allele, was stopped after a separate animal study indicated the compound could not be given as chronic repeat dosing. Roche said there was no safety concern for participants who had received a single dose, and that it stopped the study because it could no longer offer long-term treatment. The letter described the two stoppages as independent, data-driven events that "coincided by chance". The European Huntington's Disease Network, which had endorsed both studies, posted notice of the discontinuations to the community.
What the trial cannot settle is how much of the failure belongs to the idea and how much to this drug at this dose for this length of time. Independent commentary from HDBuzz, written by researchers for the HD community, noted the open questions: whether the degree of lowering achieved over roughly 16 months was deep enough, whether an intrathecal antisense drug reaches the brain regions that matter most in Huntington's, and whether treatment would need to start earlier or run longer. The trial tested one non-selective antisense oligonucleotide in a narrow, early-stage population. It did not test gene therapy, oral splice-modulating drugs, or any other huntingtin-lowering approach now in separate trials, and it carries no direct read on them.